mouse vegf elisa kit picokine (Boster Bio)


Structured Review

Mouse Vegf Elisa Kit Picokine, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse vegf elisa kit picokine/product/Boster Bio
Average 94 stars, based on 1 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury"
Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury
Journal: Theranostics
doi: 10.7150/thno.64963

Figure Legend Snippet: Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
Techniques Used: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

Figure Legend Snippet: Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P
Techniques Used: Irradiation, Enzyme-linked Immunosorbent Assay, Mouse Assay
2) Product Images from "VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types"
Article Title: VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types
Journal: Experimental and Therapeutic Medicine
doi: 10.3892/etm.2022.11176

Figure Legend Snippet: VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P
Techniques Used: Over Expression, Mouse Assay, Marker, Injection, Fluorescence, Microscopy, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Activity Assay, Standard Deviation
3) Product Images from "Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism"
Article Title: Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism
Journal: Theranostics
doi: 10.7150/thno.18816

Figure Legend Snippet: Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .
Techniques Used: Immunohistochemistry, Expressing, Mouse Assay, Infection, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Concentration Assay, Injection, Neutralization